CPT 0034U: TPMT and NUDT15 Genotyping (Mayo Clinic)
CPT code 0034U is a Proprietary Laboratory Analyses (PLA) code that identifies the Mayo Clinic’s TPMT and NUDT15 genotyping assay. The test detects genetic variants in TPMT and NUDT15 that affect thiopurine metabolism and can influence dosing and safety of thiopurine medications used in leukemia, autoimmune diseases, and transplant care. Because this is a PLA code tied to a single proprietary test, it is important for payers, laboratories, and clinicians to recognize the specific test and its clinical indications.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national overview of the code’s clinical context, descriptions of expected service settings, and what to expect in payer coverage considerations for proprietary genetic tests. The publication summarizes benchmarking topics, relevant policy and coding updates, and clinical implications of TPMT and NUDT15 genotyping for thiopurine therapy management. Data not available in the input will be noted where applicable.
Customize your policy alerts
Sign up for cpt 0034U policy alerts
Get alerted when payer policies referencing 0034U are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 0034U is a Proprietary Laboratory Analyses (PLA) code for Thiopurine Methyltransferase (TPMT) and Nudix Hydrolase 15 (NUDT15) Genotyping performed by Mayo Clinic. The test analyzes the TPMT and NUDT15 genes to detect common variants that affect thiopurine metabolism, which influences how patients process medications used for leukemia, autoimmune diseases, and prevention of organ transplant rejection.
Service Type: Genetic/genomic laboratory test (proprietary genotyping assay)
Typical Site of Service: Clinical laboratory or hospital laboratory; specimen collection may occur in outpatient clinics or physician offices